davidjohnsonq4971hires1024xx3000-1694-0-34[3].jpg
David Johnson, Ph.D.

Entrepreneur in Residence

Dr. David Johnson is an inventor, entrepreneur, and expert in genomics with a track record of bringing new medical technologies to the clinic and the market. Dave has always been an enthusiastic user of Illumina sequencing, having gained access to an early Genome Analyzer at Stanford and publishing results from his postdoc in Science Magazine in 2007. He was COO and an early employee of Natera, where he co-invented methods for non-invasive prenatal diagnosis. Natera went public in 2015 and had nearly $400 million in revenue in 2020. Subsequently, he founded GigaGen, where he invented a novel method for single-cell immune genomics, which culminated in clinical testing of the first-ever recombinant polyclonal antibody drug and sale of the company to Grifols for $142.9 million in 2021. Dave holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.